WE CLAIM:

1. A compound of Formula I, Formula II, or Formula III:



I



II



III

where:

(A) in Formula I:

each of W, X and Y is independently selected from CR^6R^7, N-R^7, O, or S provided that at least one of W, X, and Y is a non-carbon ring atom, and at least one of W, X, and Y is a carbon ring atom.

(B) In Formula II:

W and X are independently selected from C-R^6 and N, and Y is selected from CR^6R^7, N-R^7, O, or S, provided that:

(i) at least one of W, X, and Y is a non-carbon ring atom, and

(ii) when W is C-R^6 and X is N, then Y is CR^6R^7.

(C) In Formula III:

W is selected from CR^6R^7, N-R^7, O, or S, and X and Y are independently selected from C-R^6 and N, provided that:

(i) at least one of W, X, and Y is a non-carbon ring atom, and

(ii) when X is N and Y is C-R^6, then W is CR^6R^7;

and where:

Z is N or C-R^8;

each R^1, R^2, R^6, and R^8 is independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF_3, halogen, nitro, -CN, -OR^9, -SR^9, -NR^9R^{10}, -NR^9(carboxy(lower alkyl)), -C(=O)R^9, -C(=O)OR^9, -C(=O)NR^9R^{10}, -OC(=O)R^9, -SO_2R^9, -OSO_2R^9, -$SO_2NR^9R^{10}$, -$NR^9SO_2R^{10}$ or -NR^9C(=O)R^{10}, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C_{1-2} alkyl)$_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group,

R^3 and R^4 are independently, hydrogen, lower alkyl, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aryl(lower alkyl), or, together, are -$(CH_2)_{2-4}$-,

R^5 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), -C(=O)R^{11}, -C(=O)OR^{11}, -C(=O)$NR^{11}R^{12}$, -SO_2R^{11}, or -$SO_2NR^{11}R^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are -$(CH_2)_{4-6}$-,

each R^7 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), -C(=O)R^9, -C(=O)OR^9, -C(=O)NR^9R^{10}, -SO_2R^9, or -$SO_2NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C_{1-2} alkyl)$_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group,

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.

2. The compound of claim 1, where said compound is a compound of Formula I or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

3. The compound of claim 1, where said compound is a compound of Formula II or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

4. The compound of claim 1, where said compound is a compound of Formula III or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

5. The compound of claim 1 that is a compound of Formula Ia, Formula IIa, or Formula IIIa:



Ia



IIa



IIIa

where:

(A) In Formula Ia:

each of W, X and Y is independently selected from CR^6R^7, N-R^7, O, or S provided that at least one of W, X, and Y is a non-carbon ring atom, and at least one of W, X, and Y is a carbon ring atom.

(B) In Formula IIa:

W and X are independently selected from C-R^6 and N, and Y is selected from CR^6R^7, N-R^7, O, or S, provided that:

(i) at least one of W, X, and Y is a non-carbon ring atom, and

(ii) when W is C-R^6 and X is N, then Y is CR^6R^7.

(C) In Formula IIIa:

W is selected from CR^6R^7, N-R^7, O, or S, and X and Y are independently selected from C-R^6 and N, provided that:

(i) at least one of W, X, and Y is a non-carbon ring atom, and

(ii) when X is N and Y is C-R^6, then W is CR^6R^7;

and where:

Z is N or C-R^8;

R^1, R^2, R^3, R^4, R^6, R^7, and R^8 are as defined in the first embodiment,

R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF_3, halo(lower alkyl), halogen, nitro, -CN, -OR^{15}, -SR^{15}, -$NR^{15}R^{16}$, -$C(=O)R^{15}$, -$C(=O)OR^{15}$, -$C(=O)NR^{15}R^{16}$, -$OC(=O)R^{15}$, -SO_2R^{15}, -$SO_2NR^{15}R^{16}$, -$NR^{15}SO_2R^{16}$ or -$NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, -CF_3, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group,

each R^{14} is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF_3, -OR^{17}, -$NR^{17}R^{18}$, -$C(=O)R^{17}$, -$C(=O)OR^{17}$, -$O(CH_2)_mC(=O)OR^{17}$, where m is an integer of 1 to 4, or -$C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, alkenyl, alkynyl, -CF_3, optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl) or, together, are -$(CH_2)_{4-6}$-, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group, and

n is an integer of 0 to 4,

or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

6. The compound of claim 5, where said compound is a compound of Formula Ia or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

7. The compound of claim 5, where said compound is a compound of Formula IIa or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

8. The compound of claim 5, where said compound is a compound of Formula IIIa or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

9. The compound of claim 2 or claim 6, where W and Y are O, X is CR^6R^7, where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

10. The compound of claim 3 or claim 7, where W is N, X is CR^6, where R^6 is hydrogen, lower alkyl, or optionally substituted aryl, Y is O, and Z is C-H.

11. The compound of claim 4 or claim 8, where W is O, X is CR^6, where R^6 is hydrogen, lower alkyl, or optionally substituted aryl, Y is N, and Z is C-H.

12. The compound of claim 4 or claim 8, where W is N-R^7, where R^7 is hydrogen, optionally substituted lower alkyl, or optionally substituted aryl(lower alkyl), X and Y are each CR^6, where R^6 is hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

13. The compound of claim 3 or claim 7, where W and X are each CR^6, where R^6 is hydrogen, lower alkyl, or optionally substituted aryl, Y is N-R^7, where R^7 is hydrogen, lower alkyl, substituted lower alkyl, or optionally substituted aryl(lower alkyl), and Z is C-H.

14. The compound of claim 3 or claim 7, where W and X are each N, Y is N-R^7, where R^7 is hydrogen, lower alkyl, substituted lower alkyl, or optionally substituted aryl(lower alkyl), and Z is C-H.

15. The compound of claim 2 or claim 6, where W and X are each CR^6R^7, where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, Y is O, and Z is C-H.

16. The compound of claim 2 or claim 6, where W is O, X and Y are each CR^6R^7, where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

17. The compound of claim 3 or claim 7, where W is N, X is CR^6, where R^6 is hydrogen, lower alkyl, or optionally substituted aryl, Y is N-R^7, where R^7 is hydrogen, lower alkyl, substituted lower alkyl, or optionally substituted aryl(lower alkyl), and Z is C-H.

18. The compound of claim 4 or claim 8, where W is N-R^7, where R^7 is hydrogen, lower alkyl, substituted lower alkyl, or optionally substituted aryl(lower alkyl), X is CR^6, where R^6 is hydrogen, lower alkyl, or optionally substituted aryl, Y is N, and Z is C-H.

19. The compound of claim 4 or claim 8, where W is N-R^7, where R^7 is hydrogen, lower alkyl, substituted lower alkyl, or optionally substituted aryl(lower alkyl), X and Y are each N, and Z is C-H.

20. The compound of claim 1 or claim 5, where R^1 and R^2 are independently selected from hydrogen, lower alkyl, halogen, optionally lower alkyl substituted heterocycloalkyl, -OR^9, -SR^9, or -NR^9R^{10}, where R^9 and R^{10} are hydrogen, lower alkyl or optionally substituted aryl.

21. The compound of claim 1 or claim 5, where R^3 and R^4 are independently selected from hydrogen or lower alkyl.

22. The compound of claim 2 or claim 6, where W and X are each CR^6R^7, where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N-R^7.

23. The compound of claim 2 or claim 6, where W is CR^6R^7, where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, X is O, and Z is N-R^7.

24. The compound of claim 2 or claim 6, where W is O, X is CR^6R^7, where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Y is N-R^7.

25. The compound of claim 5, where R^{13} is independently selected from alkynyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -CF_3, -CN, -OR^{15}, -$C(=O)R^{15}$, -$C(=O)OR^{15}$, or -$C(=O)NR^{15}R^{16}$, where R^{15} and R^{16} are independently, hydrogen, lower alkyl, halo(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl) or R^{15} and R^{16} together are -$(CH_2)_{4-6}$-, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

26. The compound of claim 5, where R^{14} is independently selected from halogen, $-CF_3$, $-OR^{17}$, $-C(=O)OR^{17}$, $-O(CH_2)_mC(=O)OR^{17}$, where m is an integer of 1 to 4, or $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl), or R^{17} and R^{18} together are $-(CH_2)_{4-6}-$, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

27. The compound of claim 1, where R^1 is hydrogen, optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9$[carboxy(lower alkyl)], $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C_{1-2} alkyl)$_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

28. The compound of claim 1, where R^2 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, or $-C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C_{1-2} alkyl)$_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-[aryl(lower alkyl)], N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

29. The compound of claim 1 or claim 5, where R^3 and R^4 are independently, hydrogen or lower alkyl.

30. The compound of claim 1, where R^6 and R^7 are independently hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2R^9$, or $-SO_2NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally

substituted lower alkyl, lower alkyl-N(C_{1-2} alkyl)$_2$, alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

31. The compound of claim 1, where R^8 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF_3, halogen, -OR^9, -NR^9R^{10}, -C(=O)R^9, -C(=O)OR^9, -C(=O)NR^9R^{10}, -OC(=O)R^9, -SO_2R^9, -$SO_2NR^9R^{10}$, -$NR^9SO_2R^{10}$ or -NR^9C(=O)R^{10}, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C_{1-2} alkyl)$_2$, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

32. The compound of claim 1, where R^1, R^3 and R^4 are hydrogen, and R^5 is optionally substituted aryl or optionally substituted heteroaryl.

33. The compound of claim 1, where R^1, R^2, and R^8 are optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR^9, -NR^9[carboxy(lower alkyl)], -C(=O)OR^9, -C(=O)NR^9R^{10}, -$SO_2NR^9R^{10}$, or -NR^9C(=O)R^{10}, where R^9 and R^{10} are independently, hydrogen, lower alkyl, or R^9 and R^{10} together are -$(CH_2)_{4-6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

34. The compound of claim 5, where R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF_3, halogen, nitro, -CN, -OR^{15}, -SR^{15}, -$NR^{15}R^{16}$, -C(=O)R^{15}, -C(=O)OR^{15}, -C(=O)$NR^{15}R^{16}$, or -NR^{15}C(=O)R^{16}, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, or halo(lower alkyl).

35. The compound of claim 5, where each R^{14} is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF_3, -OR^{17} -$NR^{17}R^{18}$, -C(=O)R^{17}, --C(=O)OR^{17}, -$O(CH_2)_m$C(=O)OR^{17}, where m is an

integer of 1 to 4, -C(=O)NR^{17}R^{18}, where R^{17} and R^{18} are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

36. The compound of claim 1 that is selected from:

2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3-chloro-4-hydroxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3,4-dichlorophenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-({[2,6-bis(methylethyl)phenyl]amino}carbonyl)carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(4-hydroxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3-chloro-4-methoxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3-chlorophenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-[(phenylamino)carbonyl]carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(5-chloro-2-hydroxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-fluorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(2,6-difluorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(2,3-difluorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(4-fluorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(4-chlorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3,4-difluorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(4-nitrophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-nitro-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(4-bromophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-bromophenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3-cyanophenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(2,4-dichlorophenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(4-methoxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(4-iodophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3-iodophenyl)amino]carbonyl}carboxamide;
4-{[(2H-benzo[d]1,3-dioxolan-5-ylcarbonylamino)carbonyl]amino}benzamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-({[3-fluoro-4-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(4-phenylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(trifluoromethoxy)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(trifluoromethylthio)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(methylethyl)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-ethylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-ethoxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(methylethoxy)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[3-(tert-butyl)phenyl]amino}carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-phenylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chloro-4-methylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-iodo-4-methylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-({[4-methyl-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-phenoxyphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-nitrophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3,5-dichlorophenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-acetylphenyl)amino]carbonyl}carboxamide;
methyl 3-{[(2H-benzo[3,4-d]1,3-dioxolen-5-ylcarbonylamino)carbonyl]amino}benzoate;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(1H-1,2,3,4-tetraazol-5-yl)phenyl)amino]carbonyl}-carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-ethynylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chloro-2-methylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(5-chloro-2-methylphenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chloro-2,6-diethylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(5-iodo-2-methylphenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(2-pyridyl)phenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(1,3-thiazol-2-yl)phenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(3-thienyl)phenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(2-furyl)phenyl)amino]carbonyl}carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-(2-thienyl)phenyl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-[(2H-Benzo[3,4-d]1,3-dioxolen-5-ylamino)carbonyl]carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-({[5-(trifluoromethyl)(1,3,4-thiadiazol-2-yl)]amino}carbonyl)-
carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(5-chloro(1,3-thiazol-2-yl))amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(6-chloro-4-methylpyrimidin-2-yl)amino]carbonyl}carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(2-chloro(4-pyridyl))amino]carbonyl}carboxamide;
(6-bhloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-{[(3-icyanophenyl)amino]carbonyl}carboxamide;
(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-{[(3-iodophenyl)amino]carbonyl}carboxamide;
(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)-
carboxamide;
(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-({[3-(methylethoxy)phenyl]amino}carbonyl)-
carboxamide;
(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}-
carbonyl)carboxamide;
2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{[(3-chlorophenyl)methylamino]carbonyl}-N-methyl-
carboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{[(3-chlorophenyl)amino]carbonyl}-N-methylcarboxamide;
benzoxazol-5-yl-N-{[(3,4-dichlorophenyl)amino]carbonyl}carboxamide;
benzoxazol-5-yl-N-{[(4-chlorophenyl)amino]carbonyl}carboxamide;
benzoxazol-5-yl-N-{[(3-chlorophenyl)amino]carbonyl}carboxamide;
benzoxazol-5-yl-N-{[(3-bromophenyl)amino]carbonyl}carboxamide;
benzoxazol-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
benzoxazol-5-yl-N-{[(3-iodophenyl)amino]carbonyl}carboxamide;
benzoxazol-5-yl-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;

91 benzoxazol-5-yl-N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
92 benzoxazol-5-yl-N-{[(4-fluorophenyl)amino]carbonyl}carboxamide;
93 benzoxazol-6-yl-N-{[(3,4-dichlorophenyl)amino]carbonyl}carboxamide;
94 benzoxazol-6-yl-N-{[(4-chlorophenyl)amino]carbonyl}carboxamide;
95 benzoxazol-6-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
96 benzoxazol-6-yl-N-{[(3-chlorophenyl)amino]carbonyl}carboxamide;
97 benzoxazol-6-yl-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
98 benzoxazol-6-yl-N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
99 benzoxazol-6-yl-N-({[3-(trifluoromethoxy)phenyl]amino}carbonyl)carboxamide;
100 benzoxazol-6-yl-N-{[(3-cyanophenyl)amino]carbonyl}carboxamide;
101 benzoxazol-6-yl-N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
102 benzoxazol-6-yl-N-{[(3-bromophenyl)amino]carbonyl}carboxamide;
103 methyl 3-{[(benzoxazol-6-ylcarbonylamino)carbonyl]amino}benzoate;
104 4-{[(benzoxazol-6-ylcarbonylamino)carbonyl]amino}-2-chlorobenzoic acid;
105 phenylmethyl 2-(4-{[(benzoxazol-6-ylcarbonylamino)carbonyl]amino}-2-chlorophenoxy)acetate;
106 4-{[(benzoxazol-6-ylcarbonylamino)carbonyl]amino}benzoic acid;
107 5-{[(benzoxazol-6-ylcarbonylamino)carbonyl]amino}-2-chlorobenzoic acid;
108 N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)(1-methylindol-6-yl)carboxamide;
109 (1-methylindol-6-yl)-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
110 N-{[(3,4-dichlorophenyl)amino]carbonyl}(1-methylindol-6-yl)carboxamide;
111 N-{[(3-iodophenyl)amino]carbonyl}(1-methylindol-6-yl)carboxamide;
112 N-{[(3-cyanophenyl)amino]carbonyl}(1-methylindol-6-yl)carboxamide;
113 N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)(1-methylindol-6-yl)carboxamide;
114 N-{[(3,4-dichlorophenyl)amino]carbonyl}(1-methylindol-5-yl)carboxamide;
115 N-{[(3-chlorophenyl)amino]carbonyl}(1-methylindol-5-yl)carboxamide;
116 N-{[(3-bromophenyl)amino]carbonyl}(1-methylindol-5-yl)carboxamide;
117 N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)(1-methylindol-5-yl)carboxamide;
118 N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)(1-methylindol-5-yl)carboxamide;
119 benzotriazol-5-yl-N-{[(3,4-dichlorophenyl)amino]carbonyl}carboxamide;
120 benzotriazol-5-yl-N-{[(4-chlorophenyl)amino]carbonyl}carboxamide;
121 N-{[(3,4-dichlorophenyl)amino]carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;

N-{[(3-chlorophenyl)amino]carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;
2,3-dihydrobenzo[b]furan-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2,3-dihydrobenzo[b]furan-5-yl-N-{[(4-fluorophenyl)amino]carbonyl}carboxamide;
2,3-Dihydrobenzo[b]furan-5-yl-N-{[(4-methoxyphenyl)amino]carbonyl}carboxamide; and
N-{[(3,4-dichlorophenyl)amino]carbonyl}(1-methylbenzimidazol-5-yl)carboxamide;
and the pharmaceutically acceptable salts thereof, as single stereoisomers or mixtures of stereoisomers.

37. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound of claim 1; and
(b) a pharmaceutically acceptable excipient.

38. The pharmaceutical composition of claim 37, further comprising an anti-inflammatory drug, cytokine, or immunomodulator.

39. A method of treating an allergic, inflammatory, or autoimmune disorder or disease, comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need of such treatment.

40. The method of claim 39 where the compound is administered in combination with an anti-inflammatory drug, cytokine, or immunomodulator.

41. The method of claim 39 where the allergic, inflammatory, or autoimmune disorder or disease is selected from the group consisting of asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, and transplant rejection.

42. The method of claim 39 where the allergic, inflammatory, or autoimmune disorder or disease is associated with lymphocyte and/or monocyte accumulation.

43. A method of inhibiting leukocyte migration, comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need of such treatment.